According to data from Deloitte Recap LLC, there were 11 deals terminated in the first quarter of 2013, a number that is on pace to blow through the 30 terminated deals last year and the 31 terminations the year before. Read More
It has been a great quarter for public biotech companies as the sector continued to remain hot with investors. Large biotech companies, with market caps greater than $1 billion, collectively saw their share prices jump by an average of 21.5 percent in the first quarter. Read More